Funded Startups in Plan-les-ouates
Among the 10 Plan-les-ouates entries, the largest disclosed round is spineart’s $23M on 2024-03-18, and it stands out versus the rest of the disclosed amou…
Among the 10 Plan-les-ouates entries, the largest disclosed round is spineart’s $23M on 2024-03-18, and it stands out versus the rest of the disclosed amounts, where several rounds cluster in the $100K–$10M band (e.g., MPC Therapeutics $110K on 2023-11-16; Addex Therapeutics $4M on 2023-09-20; Calypso Biotech $10M on 2021-09-09). At the low end, multiple companies show $100K disclosed rounds (Endotelix 2023-03-16 $100K; Adiposs 2021-06-03 $100K), making that floor a recurring feature.
The list is also temporally back-loaded: the oldest shown round date is 2020-06-08 (Mikajaki $2M) and the newest is 2026-03-16 (Plair SA $1M), with six of 10 rounds dated 2021 or later and a concentration in 2023 (four entries: MPC Therapeutics, Addex Therapeutics, Imverse, Endotelix). Sector-wise, Biotechnology appears in 4 entries (MPC Therapeutics, Addex Therapeutics, Calypso Biotech, Adiposs), while “Series Unknown” is the most frequent round label (4 of 10: Plair SA, MPC Therapeutics, Addex Therapeutics, Imverse).
Most recent rounds
10 shownRelated listings
Frequently asked
What stands out as the largest disclosed round in Plan-les-ouates, and how does it compare to the other disclosed amounts?
spineart’s $23M round on 2024-03-18 is the largest disclosed amount in the 10-row set and is well above the next-largest disclosed figures such as Calypso Biotech’s $10M (2021-09-09) and Addex Therapeutics’ $4M (2023-09-20). Multiple other companies cluster far lower, including repeated $100K disclosures (MPC Therapeutics $110K; Endotelix $100K; Adiposs $100K).
Is there a tight cluster in time for rounds in this city listing?
Yes. Four of the 10 rounds are in 2023 (MPC Therapeutics $110K on 2023-11-16; Addex Therapeutics $4M on 2023-09-20; Imverse $440K on 2023-06-15; Endotelix $100K on 2023-03-16). Beyond that, 2021 also contributes multiple entries (Exomotion 2021-09-24 $200K; Calypso Biotech 2021-09-09 $10M; Adiposs 2021-06-03 $100K).
Which sectors are over-represented among these 10 Plan-les-ouates companies?
Biotechnology is the only sector to reach 3+ entries, appearing in 4 of 10 companies: MPC Therapeutics, Addex Therapeutics, Calypso Biotech, and Adiposs. The remaining visible sectors are represented by single entries each (Apps via Plair SA; Health Care via spineart and Endotelix; Community and Lifestyle via Imverse; Information Technology via Exomotion).
What stage labeling pattern dominates the rounds shown?
“Series Unknown” is the most common disclosed round label at 4 of 10 rows, including Plair SA (2026-03-16 $1M), MPC Therapeutics (2023-11-16 $110K), Addex Therapeutics (2023-09-20 $4M), and Imverse (2023-06-15 $440K). Labeled alternatives appear less frequently, such as Calypso Biotech’s Series A $10M (2021-09-09) and Exomotion’s Grant $200K (2021-09-24).
Which entries are potential outliers relative to the disclosed range?
The clearest high outlier is spineart’s $23M (2024-03-18), which sits above the next-largest disclosed amounts like Calypso Biotech’s $10M (2021-09-09). On the low side, several rounds cluster at the floor of disclosed figures around $100K (Endotelix $100K on 2023-03-16; Adiposs $100K on 2021-06-03), alongside small disclosures such as MPC Therapeutics $110K on 2023-11-16.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.